Semaglutide (Wegovy) Investigated for Effectiveness and Safety in Trichotillomania Treatment

Trichotillomania (hair-pulling disorder) is a body-focused repetitive behavior (BFRB) characterized by recurrent pulling out of one's hair, leading to noticeable hair loss. Current treatments often involve cognitive behavioral therapy (CBT), particularly habit reversal training, and pharmacotherapy with antidepressants (SSRIs) or N-acetylcysteine (NAC), but efficacy can be limited, and relapse rates are high. There's a significant unmet need for more effective and well-tolerated pharmacological interventions. Semaglutide, a GLP-1 receptor agonist, has shown effects on reward pathways and impulse control in other conditions, prompting investigation into its potential role in BFRBs like trichotillomania.

This study is designed to evaluate the effectiveness and safety of semaglutide (Wegovy) in individuals diagnosed with trichotillomania. Specific details regarding the study design, including participant numbers, dosage regimens, administration routes, treatment duration, and primary endpoints, are not provided in the available abstract. The study aims to assess how semaglutide impacts the symptoms of hair-pulling disorder and its overall safety profile in this patient population.

This record describes a research study currently in progress, investigating the potential therapeutic effects of semaglutide for trichotillomania. As such, the abstract does not report any specific findings, statistical outcomes, or quantitative data regarding efficacy or safety. The study's objective is to generate these findings, which will be published upon completion. No results, such as reductions in hair-pulling severity, changes in quality of life metrics, or incidence of adverse events, are available at this preliminary stage.